- Home
- TGTX vs EPR Comparison
TGTX vs EPR Comparison
Compare TGTX & EPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- EPR
- Stock Information
- Founded
- TGTX 1993
- EPR 1997
- Country
- TGTX United States
- EPR United States
- Employees
- TGTX N/A
- EPR N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- EPR Real Estate Investment Trusts
- Sector
- TGTX Health Care
- EPR Real Estate
- Exchange
- TGTX Nasdaq
- EPR Nasdaq
- Market Cap
- TGTX 4.2B
- EPR 4.1B
- IPO Year
- TGTX 1995
- EPR 1997
- Fundamental
- Price
- TGTX $29.45
- EPR $54.01
- Analyst Decision
- TGTX Strong Buy
- EPR Hold
- Analyst Count
- TGTX 4
- EPR 12
- Target Price
- TGTX $42.50
- EPR $54.05
- AVG Volume (30 Days)
- TGTX 2.9M
- EPR 982.7K
- Earning Date
- TGTX 08-04-2025
- EPR 07-30-2025
- Dividend Yield
- TGTX N/A
- EPR 6.55%
- EPS Growth
- TGTX N/A
- EPR N/A
- EPS
- TGTX 0.36
- EPR 2.03
- Revenue
- TGTX $454,069,000.00
- EPR $701,405,000.00
- Revenue This Year
- TGTX $84.00
- EPR $4.48
- Revenue Next Year
- TGTX $39.26
- EPR $2.87
- P/E Ratio
- TGTX $81.62
- EPR $26.55
- Revenue Growth
- TGTX 30.96
- EPR 1.35
- 52 Week Low
- TGTX $21.11
- EPR $41.75
- 52 Week High
- TGTX $46.48
- EPR $61.24
- Technical
- Relative Strength Index (RSI)
- TGTX 42.03
- EPR 42.77
- Support Level
- TGTX $27.23
- EPR $53.39
- Resistance Level
- TGTX $28.85
- EPR $54.27
- Average True Range (ATR)
- TGTX 1.11
- EPR 0.97
- MACD
- TGTX 0.29
- EPR 0.11
- Stochastic Oscillator
- TGTX 99.05
- EPR 63.42
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About EPR EPR Properties
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.